Safety and Efficacy of Pegfilgrastim in Patients Receiving Myelosuppressive Chemotherapy
- 1 August 2003
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 23 (8P2), 15S-19S
- https://doi.org/10.1592/phco.23.9.15s.32889
Abstract
The major dose‐limiting toxicity associated with myelosuppressive chemotherapy is neutropenia, which can be ameliorated with proactive administration of granulocyte colony‐stimulating factor (G‐CSF)....Keywords
This publication has 16 references indexed in Scilit:
- Pegylation: Engineering Improved Biopharmaceuticals for OncologyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Pharmacokinetics of PegfilgrastimPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Colony-Stimulating Factors for the Management of Neutropenia in Cancer PatientsDrugs, 2002
- Pegfilgrastim Administered Once Per Cycle Reduces Incidence of Chemotherapy-Induced NeutropeniaDrugs, 2002
- Peptide and protein PEGylation: a review of problems and solutionsBiomaterials, 2001
- The economics of febrile neutropenia: implications for the use of colony-stimulating factorsEuropean Journal of Cancer, 1998
- Filgrastim (r-metHuG-CSF): the first 10 yearsBlood, 1996
- Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEuropean Journal of Cancer, 1993
- Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trialBlood, 1992
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerNew England Journal of Medicine, 1991